Skip to main content
John Glod, MD, Pediatric Hematology & Oncology, New Brunswick, NJ

JohnGlodMD

Pediatric Hematology & Oncology New Brunswick, NJ

Assistant Professor, Pediatrics, UMDNJ-Robert Wood Johnson Medical School

Are you Dr. Glod?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 39 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. John Glod, MD is a pediatric hematologist/oncologist in New Brunswick, New Jersey. He is currently licensed to practice medicine in New Jersey, Maryland, and Ohio. He is an Assistant Professor at UMDNJ-Robert Wood Johnson Medical School.

Education & Training

  • Cincinnati Children's Hospital Medical Center
    Cincinnati Children's Hospital Medical CenterFellowship, Pediatric Hematology/Oncology, 1999 - 2000
  • Cincinnati Children's Hospital Medical Center
    Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 1996 - 1999
  • University of Colorado School of Medicine Anschutz Medical Campus
    University of Colorado School of Medicine Anschutz Medical CampusClass of 1996

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2003 - 2025
  • MD State Medical License
    MD State Medical License 2002 - 2006
  • OH State Medical License
    OH State Medical License 1997 - 2001
  • American Board of Pediatrics Pediatric Hematology-Oncology

Publications & Presentations

PubMed

Press Mentions

  • Drug Approved to Help Young Patients Battle a Rare Cancer
    Drug Approved to Help Young Patients Battle a Rare CancerJanuary 2nd, 2023
  • Slips, Slides: Winter Injuries Can Be Serious
    Slips, Slides: Winter Injuries Can Be SeriousJanuary 2nd, 2023
  • NCI Clinical Trial Leads to Atezolizumab Approval for Advanced Alveolar Soft Part Sarcoma
    NCI Clinical Trial Leads to Atezolizumab Approval for Advanced Alveolar Soft Part SarcomaDecember 28th, 2022